{"gene":"MS4A1","run_date":"2026-06-10T02:59:51","timeline":{"discoveries":[{"year":1985,"finding":"Cross-linking of CD20 (Bp35) on B cells by monoclonal antibodies stimulates B cell activation and transition through the G0-to-G1 phase of the cell cycle; monovalent Fab fragments block but do not trigger activation, indicating cross-linking is required for signaling.","method":"B cell proliferation assay with monoclonal antibodies and Fab fragments; cyclosporin A inhibition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — functional proliferation assays with multiple antibody formats across two papers (PMID:3872456 and PMID:2415587), single lab, no molecular mechanism defined","pmids":["3872456","2415587"],"is_preprint":false},{"year":1985,"finding":"CD20 (Bp35) engagement initiates transition from G0 to G1 in resting B cells as measured by RNA synthesis, cell enlargement, and responsiveness to growth factors; this effect is inhibited at low concentrations of cyclosporin A, placing CD20 at an early stage of B cell activation.","method":"Tonsillar B cell stimulation assay; thymidine uptake; cyclosporin A inhibition; monoclonal antibodies 1F5 and B1 with differing epitope specificities","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — two antibodies with different functional outcomes used to map epitope-dependent effects; single lab, functional assay without molecular mechanism","pmids":["2415587"],"is_preprint":false},{"year":1986,"finding":"CD20 (Bp35) and CD50 (Bp50) deliver distinct sequential signals in B cell activation: anti-Bp35 activates resting B cells to enter G1 (like anti-Ig), while anti-Bp50 augments progression through the cell cycle only after initial activation, functionally resembling B cell growth factor.","method":"Purified resting B cell proliferation assays; combinatorial antibody stimulation with timing experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — distinct functional outcomes with combinatorial antibody treatments in purified B cells; single lab, no downstream molecular pathway defined","pmids":["3487090"],"is_preprint":false},{"year":1987,"finding":"Anti-Bp35 (anti-CD20)-induced B cell proliferation is augmented by the same co-stimulants (BCGF, IL-1, TPA) as anti-Ig-induced proliferation; anti-Bp35 added 12–24 hours before anti-Ig or BCGF is most effective, and pretreatment converts blood B cells to an HLA-DR-bright, more activation-responsive phenotype.","method":"B cell proliferation assay; co-stimulant titration; sequential antibody addition timing experiments; HLA-DR phenotyping","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — multiple functional assays showing epistatic relationship between CD20 and Ig signaling pathways; single lab","pmids":["3492530"],"is_preprint":false},{"year":1998,"finding":"CD20 knockout mice show no major defect in B cell development, antigen receptor signaling, proliferative responses, T cell-dependent antibody responses, or calcium uptake compared to wild-type, suggesting CD20 is not essential for these processes in mice.","method":"CD20 gene disruption (knockout mice); surface marker expression; antigen receptor signaling; calcium uptake assay; proliferation assay","journal":"Immunogenetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — clean genetic knockout with multiple functional readouts; single study, negative/null result for most phenotypes","pmids":["9634476"],"is_preprint":false},{"year":2001,"finding":"FMC7 monoclonal antibody detects a conformational epitope on CD20; transient transfection of CD20 cDNA into K562 myeloid cells induces de novo expression of both CD20 and FMC7, confirming FMC7 specificity for a particular CD20 conformation (likely a multimeric CD20 complex). Rituximab treatment abolishes both CD20 and FMC7 staining.","method":"CD20 cDNA transfection into K562 cells; mutual blocking studies; flow cytometry after rituximab treatment","journal":"Cytometry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transfection reconstitution and mutual blocking with functional consequence; single lab, no structural resolution","pmids":["11309819"],"is_preprint":false},{"year":2002,"finding":"CD20 cross-linking induces apoptosis through a pathway that is independent of caspases, mitochondrial membrane potential loss, cytochrome c release, and Bcl-2, distinguishing it mechanistically from CD95- and BCR-induced apoptosis.","method":"Ramos cell CD20 cross-linking; caspase inhibitor (zVAD-fmk); Bcl-2 overexpression; annexin V staining; cytochrome c release assay; mitochondrial membrane potential measurement","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal loss-of-function approaches (genetic Bcl-2 overexpression, pharmacologic caspase inhibition) in single lab with consistent result","pmids":["12200688"],"is_preprint":false},{"year":2002,"finding":"CD20 associates with lipid raft membrane microdomains enriched in src-family tyrosine kinases; CD20 cross-linking induces lipid raft clustering and activates src-family kinase-dependent signaling pathways leading to apoptosis.","method":"Lipid raft fractionation; detergent-insolubility assay; tyrosine kinase inhibitor studies; CD20 cross-linking","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — lipid raft biochemical fractionation with functional cross-linking assay; single lab, indirect pathway activation","pmids":["12383196"],"is_preprint":false},{"year":2003,"finding":"The FMC7 antibody epitope on CD20 is sensitive to membrane cholesterol: cholesterol depletion profoundly reduces FMC7 epitope expression, while cholesterol enrichment enhances it. Mutations in the extracellular domain of CD20 abolish FMC7 reactivity. FMC7 binding induces detergent insolubility of CD20, consistent with raft association.","method":"Cholesterol depletion/enrichment experiments; CD20 extracellular domain mutagenesis; ectopic CD20 expression in hematopoietic and nonhematopoietic cell lines; flow cytometry","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-directed mutagenesis and chemical perturbation of membrane cholesterol with functional readout; single lab","pmids":["12835728"],"is_preprint":false},{"year":2004,"finding":"Mouse CD20 expression is B cell-restricted and initiated during late pre-B cell development, increasing during B cell maturation. In CD20-deficient mice, CD19-induced intracellular calcium responses are significantly reduced, demonstrating a role for CD20 in transmembrane Ca2+ movement that complements results from human CD20 cDNA-transfected cell lines.","method":"CD20-deficient (CD20-/-) mice; new panel of mouse CD20-specific mAbs; intracellular calcium response assays (CD19 and IgM-induced); B cell development analysis by flow cytometry","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic knockout with direct calcium flux assay; replicates findings from human transfected cell lines; multiple orthogonal methods in one study","pmids":["14688067"],"is_preprint":false},{"year":2005,"finding":"Purified human and murine CD20 proteins expressed in E. coli form detergent-soluble complexes with substantial helical secondary structure. Rituximab binding requires the disulfide bond between C167 and C183 in the extracellular loop; reduction and alkylation abolishes binding, which is partially recovered after reoxidation. Mutations of proposed intracellular cysteines do not affect antibody binding. Intact rituximab shows higher affinity for native B cell-surface CD20 than purified CD20, suggesting avidity effects from CD20 cross-linking into lipid rafts.","method":"E. coli expression and purification of CD20; circular dichroism spectroscopy; rituximab binding affinity measurements; cysteine mutagenesis; reduction/reoxidation experiments","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with mutagenesis and biochemical characterization; single lab with multiple orthogonal methods","pmids":["16285718"],"is_preprint":false},{"year":2012,"finding":"TGF-β-induced apoptosis of B-cell lymphoma Ramos cells is mediated by Smad-dependent transcriptional repression of MS4A1/CD20; chromatin immunoprecipitation showed Smad proteins directly bind the MS4A1 promoter. CD20 knockdown increases apoptosis, while stable CD20 overexpression confers resistance to TGF-β-induced apoptosis, establishing CD20 as a TGF-β target that promotes B cell survival.","method":"Oligonucleotide microarray; chromatin immunoprecipitation (ChIP) for Smad binding to MS4A1 promoter; CD20 knockdown and stable overexpression; apoptosis assays in vitro and in vivo","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ChIP establishing direct Smad binding, combined with gain- and loss-of-function genetic experiments with functional apoptosis readout; single lab, multiple orthogonal methods","pmids":["22665052"],"is_preprint":false},{"year":2012,"finding":"Farnesyltransferase inhibitors (FTIs, specifically L-744,832) upregulate CD20 at both mRNA and protein levels in B cell tumor lines and primary cells; ChIP reveals increased binding of transcription factors PU.1 and Oct-2 to CD20 promoter sequences upon FTI treatment, identifying a prenylation-dependent transcriptional regulatory mechanism for CD20 expression.","method":"Farnesyltransferase inhibitor treatment; qRT-PCR; flow cytometry; chromatin immunoprecipitation (ChIP) for PU.1 and Oct-2 at CD20 promoter; complement-dependent cytotoxicity assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for transcription factor binding with pharmacologic and genetic perturbation; single lab","pmids":["22843692"],"is_preprint":false},{"year":2017,"finding":"HDAC6 regulates CD20 protein levels post-transcriptionally by controlling CD20 mRNA translation; HDAC6 inhibition increases CD20 mRNA in the polysomal fraction without altering MS4A1 transcription, indicating translational rather than transcriptional regulation.","method":"HDAC6 pharmacologic inhibition and genetic knockdown; flow cytometry for CD20 protein; RT-PCR for MS4A1 mRNA; polysome fractionation; in vivo rituximab efficacy in mice","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Moderate — polysome fractionation directly measuring translational control, combined with pharmacologic and genetic HDAC6 perturbation and in vivo confirmation; single lab, multiple orthogonal methods","pmids":["28830887"],"is_preprint":false},{"year":2020,"finding":"Cryo-EM structure of full-length CD20 in complex with rituximab reveals CD20 as a compact double-barrel dimer; two rituximab Fabs each engage a composite epitope and an extensive homotypic Fab:Fab interface. The structure suggests rituximab cross-links CD20 into circular assemblies and provides a structural model for complement recruitment.","method":"Cryo-electron microscopy structure determination at 3.3 Å resolution; structure-function analysis of CD20-RTX complex","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure with functional interpretation; published in high-impact peer-reviewed journal, replicated in parallel by independent lab (PMID:32792392)","pmids":["32079680"],"is_preprint":false},{"year":2020,"finding":"Cryo-EM structures of full-length CD20 in complex with type I (rituximab, ofatumumab) and type II (obinutuzumab) therapeutic mAbs reveal mechanistic basis for type differences: type I mAb complexes act as molecular seeds for additional mAb recruitment and complement activation, while type II mAbs form terminal complexes that preclude additional mAb binding and complement component recruitment. Ofatumumab complexes display optimal geometry for complement recruitment among type I mAbs.","method":"Cryo-electron microscopy structures at 3.7–4.7 Å; binding thermodynamics measurements; structural comparison of type I vs type II mAb complexes","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple cryo-EM structures with thermodynamic validation; independent lab from PMID:32079680, replicating and extending structural findings","pmids":["32792392"],"is_preprint":false},{"year":2021,"finding":"CRISPR/Cas9-mediated ablation of CD20 in resting B cells causes relocalization of IgM-class BCR and its interaction with coreceptor CD19, leading to transient B cell activation accompanied by internalization of B cell surface markers and a PAX5-to-BLIMP-1 transcriptional switch, metabolic reprogramming toward oxidative phosphorylation, and shift toward plasma cell development. Re-expression of CD20 restores the resting state, establishing CD20 as a gatekeeper of the resting B cell state that controls nanoscale receptor organization.","method":"CRISPR/Cas9 CD20 knockout in Ramos B cells; super-resolution microscopy for receptor nanoscale organization; rescue by CD20 re-expression; transcriptome analysis; metabolic profiling; rituximab treatment of naive human B cells in vitro and in vivo","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic ablation with rescue, multiple orthogonal readouts (receptor localization, transcriptomics, metabolomics, in vivo), replicated in primary human B cells and in vivo","pmids":["33563755"],"is_preprint":false},{"year":2023,"finding":"MS4A1/CD20 mRNA is alternatively spliced into isoforms with distinct 5' UTRs (V1 and V3); V1 contains upstream open reading frames and a stem-loop that cooperatively inhibit polysome recruitment, making V1 translation-deficient while V3 supports CD20 protein expression. Splice-switching morpholino oligomers that redirect splicing from V1 to V3 enhance CD20 expression and rituximab-mediated cytotoxicity. In follicular lymphoma relapsing after mosunetuzumab, CD20 downregulation is accompanied by a V3-to-V1 splicing shift.","method":"RNA sequencing; polysome fractionation; morpholino splice-switching; CD20-knockout cell reconstitution with V1 or V3 mRNA; CAR T and bispecific antibody cytotoxicity assays; patient relapse RNA-seq","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution experiments with individual mRNA isoforms, polysome fractionation, splice-switching, and clinical validation; single lab but multiple orthogonal methods","pmids":["37683180"],"is_preprint":false},{"year":2025,"finding":"CD20 is abundantly expressed on B cell microvilli; binding of therapeutic mAbs (rituximab, ofatumumab, obinutuzumab) to CD20 on microvilli leads to antibody concentration-dependent B cell polarization and stabilization of microvilli protrusions. CD20 exists in distinct oligomeric states on the cell surface that differ in interaction with type I versus type II mAbs.","method":"Two-dye imager (TDI) DNA-PAINT super-resolution nanoscopy combined with lattice light-sheet microscopy; whole-cell volumetric imaging of endogenous CD20 on live immunological B cells","journal":"Science (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — advanced live-cell nanoscopy revealing endogenous CD20 oligomeric states and membrane dynamics; single study, no genetic perturbation to confirm functional role of microvilli localization","pmids":["39787234"],"is_preprint":false},{"year":2014,"finding":"D393-CD20, an alternative splicing isoform of CD20 that lacks membrane expression, is translated in malignant B cells and generates CD4+ Th1 epitopes recognized by tumor-infiltrating T cells; D393-CD20-specific CD4 T cell clones kill autologous lymphoma B cells, and D393-CD20 peptide vaccination induces CD4 and CD8 T cell responses in HLA-humanized transgenic mice.","method":"RT-PCR detection of D393-CD20 translation; T cell clone functional assays (IFN-γ production, cytotoxicity); peptide vaccination of HLA-humanized transgenic mice; HLA class I and II presentation assays","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional T cell killing assays and in vivo vaccination; single lab, multiple orthogonal methods","pmids":["25449106"],"is_preprint":false}],"current_model":"CD20 (MS4A1) is a B cell-specific four-transmembrane-domain phosphoprotein that forms a compact double-barrel dimer in the plasma membrane and functions as a gatekeeper of the B cell resting state by controlling nanoscale receptor organization: loss of CD20 causes IgM-BCR/CD19 co-receptor rearrangement, transient B cell activation, and transcriptional/metabolic reprogramming toward plasma cell fate; CD20 also regulates transmembrane Ca2+ conductance (particularly CD19-induced calcium responses), participates in early B cell G0-to-G1 cell cycle progression upon cross-linking, resides in cholesterol-dependent lipid raft microdomains where it associates with src-family kinases, is transcriptionally regulated by Smad proteins (downstream of TGF-β), by PU.1/Oct-2 (modulated by farnesyltransferase activity), and post-transcriptionally by HDAC6-dependent translational control and alternative splicing of its 5' UTR (with a translation-incompetent V1 isoform and a translation-competent V3 isoform); its extracellular loop disulfide (C167-C183) is required for binding of therapeutic antibodies such as rituximab, and structural studies reveal that type I antibodies (rituximab, ofatumumab) seed circular CD20 assemblies to recruit complement, while type II antibodies (obinutuzumab) form terminal complexes that preclude complement recruitment."},"narrative":{"mechanistic_narrative":"MS4A1 (CD20) is a B cell-restricted, four-transmembrane plasma membrane protein that functions as a gatekeeper of the resting B cell state by controlling the nanoscale organization of antigen receptors [PMID:33563755]. Its expression is initiated during late pre-B cell development and increases with B cell maturation, yet its loss in mice produces no major defect in B cell development, antigen receptor signaling, or proliferation [PMID:9634476, PMID:14688067]. Mechanistically, CRISPR ablation of CD20 in resting B cells triggers relocalization of the IgM-BCR and its engagement with the CD19 coreceptor, driving transient activation, a PAX5-to-BLIMP-1 transcriptional switch, metabolic reprogramming toward oxidative phosphorylation, and a shift toward plasma cell fate that is reversed by CD20 re-expression [PMID:33563755]; consistent with this coreceptor link, CD20-deficient B cells show reduced CD19-induced calcium responses [PMID:14688067]. CD20 resides in cholesterol-dependent lipid raft microdomains enriched in src-family kinases, and antibody cross-linking clusters these rafts and drives a caspase-, mitochondria-, and Bcl-2-independent apoptotic pathway [PMID:12200688, PMID:12383196, PMID:12835728]. Structurally, CD20 forms a compact double-barrel dimer whose extracellular C167–C183 disulfide is required for rituximab binding; type I antibodies (rituximab, ofatumumab) seed circular CD20 assemblies that recruit complement, while type II antibodies (obinutuzumab) form terminal complexes that preclude complement recruitment [PMID:16285718, PMID:32079680, PMID:32792392]. CD20 abundance is controlled at multiple levels: transcriptionally by Smad proteins downstream of TGF-β (where CD20 promotes survival by resisting TGF-β-induced apoptosis) and by PU.1/Oct-2 under prenylation control, and post-transcriptionally by HDAC6-dependent translational control and by alternative 5' UTR splicing that generates a translation-deficient V1 and a translation-competent V3 isoform [PMID:22665052, PMID:22843692, PMID:28830887, PMID:37683180].","teleology":[{"year":1987,"claim":"Established the earliest functional role of CD20 by showing that antibody cross-linking, but not monovalent engagement, drives resting B cells from G0 into G1 in concert with the Ig-signaling pathway, placing CD20 at an early activation checkpoint.","evidence":"B cell proliferation and cell-cycle assays with cross-linking versus Fab fragments, sequential antibody timing, and co-stimulant titration","pmids":["3872456","2415587","3487090","3492530"],"confidence":"Medium","gaps":["No molecular signaling pathway downstream of CD20 defined","Mechanism of how cross-linking couples to cell-cycle entry unknown"]},{"year":1998,"claim":"Tested whether CD20 is genetically required for B cell biology; knockout mice showed largely normal development and signaling, indicating CD20 is dispensable for core B cell functions in mice and reframing it as a modulator rather than an essential receptor.","evidence":"CD20 gene-disruption mice with development, signaling, proliferation, and calcium-uptake readouts","pmids":["9634476"],"confidence":"Medium","gaps":["Negative result does not exclude subtle or redundant roles","Does not address human CD20 function or therapeutic relevance"]},{"year":2004,"claim":"Refined CD20's role in calcium handling by showing that CD20-deficient B cells have reduced CD19-induced calcium responses, linking CD20 to coreceptor-dependent transmembrane Ca2+ movement.","evidence":"CD20-deficient mice with CD19- and IgM-induced intracellular calcium assays and developmental flow cytometry","pmids":["14688067"],"confidence":"High","gaps":["Whether CD20 itself conducts ions or acts indirectly via CD19 unresolved","Molecular link between CD20 and the calcium machinery undefined"]},{"year":2003,"claim":"Connected CD20 to membrane microdomain biology by showing its raft association is cholesterol-dependent and that cross-linking clusters rafts to engage src-family kinases and drive a non-canonical apoptotic pathway.","evidence":"Lipid raft fractionation, cholesterol depletion/enrichment, extracellular-domain mutagenesis, kinase inhibition, and apoptosis assays","pmids":["12200688","12383196","12835728"],"confidence":"Medium","gaps":["Identity of the src-family kinases and apoptotic effectors not defined","Physiological relevance of cross-linking-induced apoptosis unclear"]},{"year":2005,"claim":"Defined the molecular determinant of therapeutic antibody binding by showing the extracellular C167–C183 disulfide is required for rituximab recognition and that surface CD20 binds with higher avidity than purified protein.","evidence":"E. coli expression and purification, circular dichroism, cysteine mutagenesis, reduction/reoxidation, and rituximab affinity measurements","pmids":["16285718"],"confidence":"High","gaps":["Full conformational epitope not resolved at this stage","Oligomeric state on the membrane not directly visualized"]},{"year":2012,"claim":"Resolved how CD20 expression is transcriptionally controlled, identifying Smad-mediated repression downstream of TGF-β (with CD20 promoting survival) and PU.1/Oct-2 activation under prenylation control.","evidence":"ChIP for Smad, PU.1 and Oct-2 at the MS4A1 promoter, knockdown/overexpression, farnesyltransferase inhibition, and apoptosis/CDC assays","pmids":["22665052","22843692"],"confidence":"High","gaps":["How TGF-β/Smad and PU.1/Oct-2 inputs are integrated unknown","Mechanism by which CD20 confers apoptosis resistance not defined"]},{"year":2017,"claim":"Extended CD20 regulation beyond transcription by showing HDAC6 controls CD20 protein levels through translational regulation of its mRNA, with direct relevance to rituximab efficacy.","evidence":"HDAC6 pharmacologic inhibition and knockdown, polysome fractionation, mRNA quantification, and in vivo rituximab efficacy","pmids":["28830887"],"confidence":"High","gaps":["Direct molecular link between HDAC6 and the CD20 translation machinery not defined","Acetylation substrate mediating the effect unidentified"]},{"year":2020,"claim":"Provided the structural basis for CD20 architecture and antibody-class differences, revealing a double-barrel dimer and explaining why type I antibodies seed complement-recruiting assemblies while type II antibodies form terminal complexes.","evidence":"Cryo-EM structures of full-length CD20 bound to type I and type II mAbs with binding thermodynamics, from two independent labs","pmids":["32079680","32792392"],"confidence":"High","gaps":["Structure of unliganded native oligomers not resolved","Endogenous oligomeric distribution on live cells not addressed"]},{"year":2021,"claim":"Established CD20's core physiological function as a gatekeeper of the resting B cell state, showing its loss reorganizes the IgM-BCR/CD19 axis and drives a transcriptional and metabolic shift toward plasma cell fate that is reversible upon re-expression.","evidence":"CRISPR knockout with rescue, super-resolution microscopy, transcriptomics, metabolic profiling, and primary human B cell/in vivo validation","pmids":["33563755"],"confidence":"High","gaps":["Direct molecular interaction between CD20 and BCR/CD19 not structurally defined","How CD20 physically constrains receptor nanoscale organization unknown"]},{"year":2023,"claim":"Identified a post-transcriptional resistance mechanism, showing 5' UTR alternative splicing generates a translation-deficient V1 and translation-competent V3 isoform, with V3-to-V1 shifts driving CD20 loss in lymphoma relapse.","evidence":"RNA-seq, polysome fractionation, splice-switching morpholinos, isoform reconstitution, immunotherapy cytotoxicity assays, and patient relapse RNA-seq","pmids":["37683180"],"confidence":"High","gaps":["Upstream regulators controlling the V1/V3 splicing decision unknown","Generalizability across lymphoma subtypes not established"]},{"year":2025,"claim":"Localized endogenous CD20 to B cell microvilli and showed antibody binding induces polarization and microvilli stabilization, with distinct oligomeric states differentially engaging type I versus type II mAbs.","evidence":"DNA-PAINT super-resolution nanoscopy with lattice light-sheet imaging of endogenous CD20 on live B cells","pmids":["39787234"],"confidence":"Medium","gaps":["No genetic perturbation to confirm functional role of microvilli localization","Molecular basis distinguishing the oligomeric states undefined"]},{"year":null,"claim":"How CD20 mechanically organizes the BCR/CD19 nanocluster and whether its oligomeric and microvilli distribution directly governs ion conductance and resting-state maintenance remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No structure of CD20 in complex with BCR or CD19","Mechanism coupling CD20 oligomeric state to calcium conductance undefined","Direct effectors of CD20-dependent receptor confinement unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[9]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[7,8,16,18]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,9,16]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[6,11]}],"complexes":[],"partners":["CD19","MS4A1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P11836","full_name":"B-lymphocyte antigen CD20","aliases":["B-lymphocyte surface antigen B1","Bp35","Leukocyte surface antigen Leu-16","Membrane-spanning 4-domains subfamily A member 1"],"length_aa":297,"mass_kda":33.1,"function":"B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes (PubMed:12920111, PubMed:3925015, PubMed:7684739). Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR (PubMed:12920111, PubMed:18474602, PubMed:7684739)","subcellular_location":"Cell membrane; Cell membrane","url":"https://www.uniprot.org/uniprotkb/P11836/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MS4A1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MS4A1","total_profiled":1310},"omim":[{"mim_id":"613495","title":"IMMUNODEFICIENCY, COMMON VARIABLE, 5; CVID5","url":"https://www.omim.org/entry/613495"},{"mim_id":"606550","title":"MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 12; MS4A12","url":"https://www.omim.org/entry/606550"},{"mim_id":"606549","title":"MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 8B; MS4A8B","url":"https://www.omim.org/entry/606549"},{"mim_id":"606548","title":"MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 6A; MS4A6A","url":"https://www.omim.org/entry/606548"},{"mim_id":"606547","title":"MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 4A; MS4A4A","url":"https://www.omim.org/entry/606547"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":631.0}],"url":"https://www.proteinatlas.org/search/MS4A1"},"hgnc":{"alias_symbol":["B1","Bp35","FMC7"],"prev_symbol":["CD20"]},"alphafold":{"accession":"P11836","domains":[{"cath_id":"-","chopping":"40-243","consensus_level":"high","plddt":82.5539,"start":40,"end":243}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11836","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11836-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11836-F1-predicted_aligned_error_v6.png","plddt_mean":70.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MS4A1","jax_strain_url":"https://www.jax.org/strain/search?query=MS4A1"},"sequence":{"accession":"P11836","fasta_url":"https://rest.uniprot.org/uniprotkb/P11836.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11836/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11836"}},"corpus_meta":[{"pmid":"7524522","id":"PMC_7524522","title":"CD20: a regulator of cell-cycle progression of B lymphocytes.","date":"1994","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/7524522","citation_count":499,"is_preprint":false},{"pmid":"3487090","id":"PMC_3487090","title":"Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3487090","citation_count":496,"is_preprint":false},{"pmid":"17768100","id":"PMC_17768100","title":"Mechanisms of killing by anti-CD20 monoclonal antibodies.","date":"2007","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17768100","citation_count":415,"is_preprint":false},{"pmid":"32482755","id":"PMC_32482755","title":"The regulation and function of CD20: an \"enigma\" of B-cell biology and targeted therapy.","date":"2020","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/32482755","citation_count":333,"is_preprint":false},{"pmid":"9708202","id":"PMC_9708202","title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias.","date":"1998","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9708202","citation_count":258,"is_preprint":false},{"pmid":"15564720","id":"PMC_15564720","title":"The biology of CD20 and its potential as a target for mAb therapy.","date":"2005","source":"Current directions in autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/15564720","citation_count":240,"is_preprint":false},{"pmid":"3872456","id":"PMC_3872456","title":"Role of the Bp35 cell surface polypeptide in human B-cell activation.","date":"1985","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3872456","citation_count":211,"is_preprint":false},{"pmid":"29716920","id":"PMC_29716920","title":"CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29716920","citation_count":203,"is_preprint":false},{"pmid":"14688067","id":"PMC_14688067","title":"Mouse CD20 expression and function.","date":"2004","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14688067","citation_count":187,"is_preprint":false},{"pmid":"19773256","id":"PMC_19773256","title":"Anti-CD20 monoclonal antibodies: historical and future perspectives.","date":"2009","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/19773256","citation_count":185,"is_preprint":false},{"pmid":"12383196","id":"PMC_12383196","title":"CD20-mediated apoptosis: signalling through lipid rafts.","date":"2002","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12383196","citation_count":184,"is_preprint":false},{"pmid":"2415587","id":"PMC_2415587","title":"The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle.","date":"1985","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2415587","citation_count":171,"is_preprint":false},{"pmid":"32079680","id":"PMC_32079680","title":"Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32079680","citation_count":150,"is_preprint":false},{"pmid":"28695471","id":"PMC_28695471","title":"Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.","date":"2017","source":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28695471","citation_count":147,"is_preprint":false},{"pmid":"29046676","id":"PMC_29046676","title":"Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29046676","citation_count":137,"is_preprint":false},{"pmid":"18585457","id":"PMC_18585457","title":"Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.","date":"2008","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18585457","citation_count":125,"is_preprint":false},{"pmid":"29593838","id":"PMC_29593838","title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.","date":"2018","source":"Therapeutic advances in neurological disorders","url":"https://pubmed.ncbi.nlm.nih.gov/29593838","citation_count":111,"is_preprint":false},{"pmid":"16169773","id":"PMC_16169773","title":"The therapeutic potential of anti-CD20 \"what do B-cells do?\".","date":"2005","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/16169773","citation_count":107,"is_preprint":false},{"pmid":"32792392","id":"PMC_32792392","title":"Binding mechanisms of therapeutic antibodies to human CD20.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32792392","citation_count":105,"is_preprint":false},{"pmid":"23057966","id":"PMC_23057966","title":"Novel CD20 monoclonal antibodies for lymphoma therapy.","date":"2012","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23057966","citation_count":104,"is_preprint":false},{"pmid":"37033984","id":"PMC_37033984","title":"Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37033984","citation_count":102,"is_preprint":false},{"pmid":"11225995","id":"PMC_11225995","title":"CD20: a gene in search of a function.","date":"2000","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11225995","citation_count":102,"is_preprint":false},{"pmid":"6788112","id":"PMC_6788112","title":"Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7.","date":"1981","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/6788112","citation_count":92,"is_preprint":false},{"pmid":"30096012","id":"PMC_30096012","title":"Anti-CD20 monoclonal antibodies: reviewing a revolution.","date":"2018","source":"Human vaccines & immunotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/30096012","citation_count":91,"is_preprint":false},{"pmid":"9634476","id":"PMC_9634476","title":"Mice carrying a CD20 gene disruption.","date":"1998","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/9634476","citation_count":88,"is_preprint":false},{"pmid":"18318769","id":"PMC_18318769","title":"Anti-CD20 monoclonal antibody therapy in multiple myeloma.","date":"2008","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/18318769","citation_count":87,"is_preprint":false},{"pmid":"33563755","id":"PMC_33563755","title":"CD20 as a gatekeeper of the resting state of human B cells.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33563755","citation_count":85,"is_preprint":false},{"pmid":"20081379","id":"PMC_20081379","title":"Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.","date":"2010","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/20081379","citation_count":80,"is_preprint":false},{"pmid":"26585985","id":"PMC_26585985","title":"Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.","date":"2015","source":"Clinical journal of the American Society of Nephrology : CJASN","url":"https://pubmed.ncbi.nlm.nih.gov/26585985","citation_count":78,"is_preprint":false},{"pmid":"3492530","id":"PMC_3492530","title":"Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors.","date":"1987","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3492530","citation_count":77,"is_preprint":false},{"pmid":"12200688","id":"PMC_12200688","title":"CD20-induced B cell death can bypass mitochondria and caspase activation.","date":"2002","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/12200688","citation_count":73,"is_preprint":false},{"pmid":"35353539","id":"PMC_35353539","title":"Proinflammatory CD20+ T cells contribute to CNS-directed autoimmunity.","date":"2022","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35353539","citation_count":71,"is_preprint":false},{"pmid":"20350667","id":"PMC_20350667","title":"CD20-targeted therapy: the next generation of antibodies.","date":"2010","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/20350667","citation_count":71,"is_preprint":false},{"pmid":"20367564","id":"PMC_20367564","title":"The future of CD20 monoclonal antibody therapy in B-cell malignancies.","date":"2010","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/20367564","citation_count":68,"is_preprint":false},{"pmid":"30089638","id":"PMC_30089638","title":"Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.","date":"2018","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30089638","citation_count":68,"is_preprint":false},{"pmid":"33092190","id":"PMC_33092190","title":"Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab.","date":"2020","source":"Brain sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33092190","citation_count":66,"is_preprint":false},{"pmid":"16285718","id":"PMC_16285718","title":"Isolation and characterization of the B-cell marker CD20.","date":"2005","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16285718","citation_count":66,"is_preprint":false},{"pmid":"21486448","id":"PMC_21486448","title":"The predictive significance of CD20 expression in B-cell lymphomas.","date":"2011","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21486448","citation_count":58,"is_preprint":false},{"pmid":"25733518","id":"PMC_25733518","title":"Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia.","date":"2015","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/25733518","citation_count":57,"is_preprint":false},{"pmid":"38480630","id":"PMC_38480630","title":"Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability.","date":"2024","source":"Drugs","url":"https://pubmed.ncbi.nlm.nih.gov/38480630","citation_count":54,"is_preprint":false},{"pmid":"31994023","id":"PMC_31994023","title":"Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.","date":"2020","source":"CNS drugs","url":"https://pubmed.ncbi.nlm.nih.gov/31994023","citation_count":54,"is_preprint":false},{"pmid":"35634306","id":"PMC_35634306","title":"CD20+CD22+ADAM28+ B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35634306","citation_count":54,"is_preprint":false},{"pmid":"30551501","id":"PMC_30551501","title":"The applications of anti-CD20 antibodies to treat various B cells disorders.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30551501","citation_count":50,"is_preprint":false},{"pmid":"30792198","id":"PMC_30792198","title":"CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.","date":"2019","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/30792198","citation_count":50,"is_preprint":false},{"pmid":"15047755","id":"PMC_15047755","title":"CD20 positive T cell lymphoma: is it a real entity?","date":"2004","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15047755","citation_count":48,"is_preprint":false},{"pmid":"17299094","id":"PMC_17299094","title":"T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17299094","citation_count":47,"is_preprint":false},{"pmid":"30639700","id":"PMC_30639700","title":"CD3+CD20+ T cells and their roles in human diseases.","date":"2019","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30639700","citation_count":45,"is_preprint":false},{"pmid":"23953071","id":"PMC_23953071","title":"Anti-CD20 monoclonal antibodies: beyond B-cells.","date":"2013","source":"Blood reviews","url":"https://pubmed.ncbi.nlm.nih.gov/23953071","citation_count":45,"is_preprint":false},{"pmid":"28830887","id":"PMC_28830887","title":"HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28830887","citation_count":45,"is_preprint":false},{"pmid":"33547368","id":"PMC_33547368","title":"Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33547368","citation_count":45,"is_preprint":false},{"pmid":"34235400","id":"PMC_34235400","title":"COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma.","date":"2021","source":"HemaSphere","url":"https://pubmed.ncbi.nlm.nih.gov/34235400","citation_count":45,"is_preprint":false},{"pmid":"25014645","id":"PMC_25014645","title":"Obinutuzumab: a new class of anti-CD20 monoclonal antibody.","date":"2014","source":"Current opinion in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25014645","citation_count":44,"is_preprint":false},{"pmid":"33352466","id":"PMC_33352466","title":"MS4A1 expression and function in T cells in the colorectal cancer tumor microenvironment.","date":"2020","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33352466","citation_count":42,"is_preprint":false},{"pmid":"37683180","id":"PMC_37683180","title":"Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/37683180","citation_count":40,"is_preprint":false},{"pmid":"27354469","id":"PMC_27354469","title":"CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27354469","citation_count":38,"is_preprint":false},{"pmid":"27718747","id":"PMC_27718747","title":"Anti-CD20 monoclonal antibodies in multiple sclerosis.","date":"2016","source":"Expert review of neurotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27718747","citation_count":38,"is_preprint":false},{"pmid":"21196171","id":"PMC_21196171","title":"Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.","date":"2011","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/21196171","citation_count":38,"is_preprint":false},{"pmid":"17575162","id":"PMC_17575162","title":"Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17575162","citation_count":38,"is_preprint":false},{"pmid":"38253219","id":"PMC_38253219","title":"scRNA-seq of colorectal cancer shows regional immune atlas with the function of CD20+ B cells.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38253219","citation_count":37,"is_preprint":false},{"pmid":"35222385","id":"PMC_35222385","title":"New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35222385","citation_count":36,"is_preprint":false},{"pmid":"14608903","id":"PMC_14608903","title":"Diagnostic significance of CD20 and FMC7 expression in B-cell disorders.","date":"2003","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14608903","citation_count":36,"is_preprint":false},{"pmid":"35951029","id":"PMC_35951029","title":"CD20+ T cells: an emerging T cell subset in human pathology.","date":"2022","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/35951029","citation_count":36,"is_preprint":false},{"pmid":"25449106","id":"PMC_25449106","title":"CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes.","date":"2014","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25449106","citation_count":36,"is_preprint":false},{"pmid":"15195108","id":"PMC_15195108","title":"Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray.","date":"2004","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/15195108","citation_count":35,"is_preprint":false},{"pmid":"25086174","id":"PMC_25086174","title":"Translational medicine in action: anti-CD20 therapy in lymphoma.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25086174","citation_count":34,"is_preprint":false},{"pmid":"22665052","id":"PMC_22665052","title":"TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22665052","citation_count":32,"is_preprint":false},{"pmid":"28191314","id":"PMC_28191314","title":"Diagnosis and treatment of CD20 negative B cell lymphomas.","date":"2017","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/28191314","citation_count":32,"is_preprint":false},{"pmid":"8135183","id":"PMC_8135183","title":"Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody.","date":"1994","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8135183","citation_count":32,"is_preprint":false},{"pmid":"34263696","id":"PMC_34263696","title":"Glofitamab CD20-TCB bispecific antibody.","date":"2021","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/34263696","citation_count":30,"is_preprint":false},{"pmid":"16550338","id":"PMC_16550338","title":"Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies.","date":"2006","source":"Clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16550338","citation_count":30,"is_preprint":false},{"pmid":"28614191","id":"PMC_28614191","title":"Anti-CD20 Blocker Rituximab in Kidney Transplantation.","date":"2018","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/28614191","citation_count":29,"is_preprint":false},{"pmid":"33551958","id":"PMC_33551958","title":"Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis.","date":"2021","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33551958","citation_count":29,"is_preprint":false},{"pmid":"35967378","id":"PMC_35967378","title":"Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35967378","citation_count":28,"is_preprint":false},{"pmid":"36631511","id":"PMC_36631511","title":"Modeling and affinity maturation of an anti-CD20 nanobody: a comprehensive in-silico investigation.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36631511","citation_count":26,"is_preprint":false},{"pmid":"11309819","id":"PMC_11309819","title":"Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses.","date":"2001","source":"Cytometry","url":"https://pubmed.ncbi.nlm.nih.gov/11309819","citation_count":25,"is_preprint":false},{"pmid":"1376065","id":"PMC_1376065","title":"CD20 and CD5 expression in B-chronic lymphocytic leukemia.","date":"1992","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/1376065","citation_count":25,"is_preprint":false},{"pmid":"34252986","id":"PMC_34252986","title":"Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/34252986","citation_count":24,"is_preprint":false},{"pmid":"22514692","id":"PMC_22514692","title":"MS4A1 dysregulation in asbestos-related lung squamous cell carcinoma is due to CD20 stromal lymphocyte expression.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22514692","citation_count":23,"is_preprint":false},{"pmid":"28067179","id":"PMC_28067179","title":"CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies.","date":"2017","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/28067179","citation_count":22,"is_preprint":false},{"pmid":"27531574","id":"PMC_27531574","title":"Anti-CD20 antibody treatment of non-Hodgkin lymphomas.","date":"2016","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/27531574","citation_count":22,"is_preprint":false},{"pmid":"24696233","id":"PMC_24696233","title":"CD20+ B cell depletion alters T cell homing.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24696233","citation_count":22,"is_preprint":false},{"pmid":"24467775","id":"PMC_24467775","title":"Mycosis fungoides with CD20 expression: report of two cases and review of the literature.","date":"2014","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24467775","citation_count":22,"is_preprint":false},{"pmid":"11857591","id":"PMC_11857591","title":"Clinical utility of CD23 and FMC7 antigen coexistent expression in B-cell lymphoproliferative disorder subclassification.","date":"2002","source":"Cytometry","url":"https://pubmed.ncbi.nlm.nih.gov/11857591","citation_count":21,"is_preprint":false},{"pmid":"22647435","id":"PMC_22647435","title":"Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study.","date":"2012","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/22647435","citation_count":19,"is_preprint":false},{"pmid":"36251156","id":"PMC_36251156","title":"Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently.","date":"2022","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36251156","citation_count":18,"is_preprint":false},{"pmid":"37369602","id":"PMC_37369602","title":"Intrathecal CD8+CD20+ T Cells in Primary Progressive Multiple Sclerosis.","date":"2023","source":"Neurology(R) neuroimmunology & neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37369602","citation_count":18,"is_preprint":false},{"pmid":"18713565","id":"PMC_18713565","title":"Spotlight on anti-CD20.","date":"2008","source":"International MS journal","url":"https://pubmed.ncbi.nlm.nih.gov/18713565","citation_count":18,"is_preprint":false},{"pmid":"22843692","id":"PMC_22843692","title":"Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22843692","citation_count":18,"is_preprint":false},{"pmid":"32744145","id":"PMC_32744145","title":"Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies.","date":"2020","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/32744145","citation_count":18,"is_preprint":false},{"pmid":"36409926","id":"PMC_36409926","title":"Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR.","date":"2023","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/36409926","citation_count":17,"is_preprint":false},{"pmid":"12835728","id":"PMC_12835728","title":"A cholesterol-dependent CD20 epitope detected by the FMC7 antibody.","date":"2003","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/12835728","citation_count":17,"is_preprint":false},{"pmid":"39787234","id":"PMC_39787234","title":"Decoding the molecular interplay of CD20 and therapeutic antibodies with fast volumetric nanoscopy.","date":"2025","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/39787234","citation_count":17,"is_preprint":false},{"pmid":"9579603","id":"PMC_9579603","title":"FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20.","date":"1998","source":"Cytometry","url":"https://pubmed.ncbi.nlm.nih.gov/9579603","citation_count":16,"is_preprint":false},{"pmid":"17722077","id":"PMC_17722077","title":"Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.","date":"2008","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/17722077","citation_count":16,"is_preprint":false},{"pmid":"24670986","id":"PMC_24670986","title":"Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.","date":"2014","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/24670986","citation_count":16,"is_preprint":false},{"pmid":"33288390","id":"PMC_33288390","title":"Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus.","date":"2020","source":"Biologicals : journal of the International Association of Biological Standardization","url":"https://pubmed.ncbi.nlm.nih.gov/33288390","citation_count":15,"is_preprint":false},{"pmid":"3257502","id":"PMC_3257502","title":"Functional properties of human B cell subpopulations defined by monoclonal antibodies HB4 and FMC7.","date":"1988","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3257502","citation_count":15,"is_preprint":false},{"pmid":"20109133","id":"PMC_20109133","title":"Ofatumumab, a human anti-CD20 monoclonal antibody.","date":"2010","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/20109133","citation_count":15,"is_preprint":false},{"pmid":"36704890","id":"PMC_36704890","title":"Adriamycin-loaded exosome with anti-CD20 aptamers selectively suppresses human CD20+ melanoma stem cells.","date":"2023","source":"Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)","url":"https://pubmed.ncbi.nlm.nih.gov/36704890","citation_count":15,"is_preprint":false},{"pmid":"12959352","id":"PMC_12959352","title":"Immunotherapy with anti-CD20 compounds.","date":"2003","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/12959352","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44927,"output_tokens":5506,"usd":0.108686,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14094,"output_tokens":3898,"usd":0.08396,"stage2_stop_reason":"end_turn"},"total_usd":0.192646,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1985,\n      \"finding\": \"Cross-linking of CD20 (Bp35) on B cells by monoclonal antibodies stimulates B cell activation and transition through the G0-to-G1 phase of the cell cycle; monovalent Fab fragments block but do not trigger activation, indicating cross-linking is required for signaling.\",\n      \"method\": \"B cell proliferation assay with monoclonal antibodies and Fab fragments; cyclosporin A inhibition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — functional proliferation assays with multiple antibody formats across two papers (PMID:3872456 and PMID:2415587), single lab, no molecular mechanism defined\",\n      \"pmids\": [\"3872456\", \"2415587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"CD20 (Bp35) engagement initiates transition from G0 to G1 in resting B cells as measured by RNA synthesis, cell enlargement, and responsiveness to growth factors; this effect is inhibited at low concentrations of cyclosporin A, placing CD20 at an early stage of B cell activation.\",\n      \"method\": \"Tonsillar B cell stimulation assay; thymidine uptake; cyclosporin A inhibition; monoclonal antibodies 1F5 and B1 with differing epitope specificities\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — two antibodies with different functional outcomes used to map epitope-dependent effects; single lab, functional assay without molecular mechanism\",\n      \"pmids\": [\"2415587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"CD20 (Bp35) and CD50 (Bp50) deliver distinct sequential signals in B cell activation: anti-Bp35 activates resting B cells to enter G1 (like anti-Ig), while anti-Bp50 augments progression through the cell cycle only after initial activation, functionally resembling B cell growth factor.\",\n      \"method\": \"Purified resting B cell proliferation assays; combinatorial antibody stimulation with timing experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — distinct functional outcomes with combinatorial antibody treatments in purified B cells; single lab, no downstream molecular pathway defined\",\n      \"pmids\": [\"3487090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"Anti-Bp35 (anti-CD20)-induced B cell proliferation is augmented by the same co-stimulants (BCGF, IL-1, TPA) as anti-Ig-induced proliferation; anti-Bp35 added 12–24 hours before anti-Ig or BCGF is most effective, and pretreatment converts blood B cells to an HLA-DR-bright, more activation-responsive phenotype.\",\n      \"method\": \"B cell proliferation assay; co-stimulant titration; sequential antibody addition timing experiments; HLA-DR phenotyping\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple functional assays showing epistatic relationship between CD20 and Ig signaling pathways; single lab\",\n      \"pmids\": [\"3492530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CD20 knockout mice show no major defect in B cell development, antigen receptor signaling, proliferative responses, T cell-dependent antibody responses, or calcium uptake compared to wild-type, suggesting CD20 is not essential for these processes in mice.\",\n      \"method\": \"CD20 gene disruption (knockout mice); surface marker expression; antigen receptor signaling; calcium uptake assay; proliferation assay\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — clean genetic knockout with multiple functional readouts; single study, negative/null result for most phenotypes\",\n      \"pmids\": [\"9634476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FMC7 monoclonal antibody detects a conformational epitope on CD20; transient transfection of CD20 cDNA into K562 myeloid cells induces de novo expression of both CD20 and FMC7, confirming FMC7 specificity for a particular CD20 conformation (likely a multimeric CD20 complex). Rituximab treatment abolishes both CD20 and FMC7 staining.\",\n      \"method\": \"CD20 cDNA transfection into K562 cells; mutual blocking studies; flow cytometry after rituximab treatment\",\n      \"journal\": \"Cytometry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transfection reconstitution and mutual blocking with functional consequence; single lab, no structural resolution\",\n      \"pmids\": [\"11309819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD20 cross-linking induces apoptosis through a pathway that is independent of caspases, mitochondrial membrane potential loss, cytochrome c release, and Bcl-2, distinguishing it mechanistically from CD95- and BCR-induced apoptosis.\",\n      \"method\": \"Ramos cell CD20 cross-linking; caspase inhibitor (zVAD-fmk); Bcl-2 overexpression; annexin V staining; cytochrome c release assay; mitochondrial membrane potential measurement\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal loss-of-function approaches (genetic Bcl-2 overexpression, pharmacologic caspase inhibition) in single lab with consistent result\",\n      \"pmids\": [\"12200688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD20 associates with lipid raft membrane microdomains enriched in src-family tyrosine kinases; CD20 cross-linking induces lipid raft clustering and activates src-family kinase-dependent signaling pathways leading to apoptosis.\",\n      \"method\": \"Lipid raft fractionation; detergent-insolubility assay; tyrosine kinase inhibitor studies; CD20 cross-linking\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — lipid raft biochemical fractionation with functional cross-linking assay; single lab, indirect pathway activation\",\n      \"pmids\": [\"12383196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The FMC7 antibody epitope on CD20 is sensitive to membrane cholesterol: cholesterol depletion profoundly reduces FMC7 epitope expression, while cholesterol enrichment enhances it. Mutations in the extracellular domain of CD20 abolish FMC7 reactivity. FMC7 binding induces detergent insolubility of CD20, consistent with raft association.\",\n      \"method\": \"Cholesterol depletion/enrichment experiments; CD20 extracellular domain mutagenesis; ectopic CD20 expression in hematopoietic and nonhematopoietic cell lines; flow cytometry\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-directed mutagenesis and chemical perturbation of membrane cholesterol with functional readout; single lab\",\n      \"pmids\": [\"12835728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Mouse CD20 expression is B cell-restricted and initiated during late pre-B cell development, increasing during B cell maturation. In CD20-deficient mice, CD19-induced intracellular calcium responses are significantly reduced, demonstrating a role for CD20 in transmembrane Ca2+ movement that complements results from human CD20 cDNA-transfected cell lines.\",\n      \"method\": \"CD20-deficient (CD20-/-) mice; new panel of mouse CD20-specific mAbs; intracellular calcium response assays (CD19 and IgM-induced); B cell development analysis by flow cytometry\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic knockout with direct calcium flux assay; replicates findings from human transfected cell lines; multiple orthogonal methods in one study\",\n      \"pmids\": [\"14688067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Purified human and murine CD20 proteins expressed in E. coli form detergent-soluble complexes with substantial helical secondary structure. Rituximab binding requires the disulfide bond between C167 and C183 in the extracellular loop; reduction and alkylation abolishes binding, which is partially recovered after reoxidation. Mutations of proposed intracellular cysteines do not affect antibody binding. Intact rituximab shows higher affinity for native B cell-surface CD20 than purified CD20, suggesting avidity effects from CD20 cross-linking into lipid rafts.\",\n      \"method\": \"E. coli expression and purification of CD20; circular dichroism spectroscopy; rituximab binding affinity measurements; cysteine mutagenesis; reduction/reoxidation experiments\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with mutagenesis and biochemical characterization; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"16285718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TGF-β-induced apoptosis of B-cell lymphoma Ramos cells is mediated by Smad-dependent transcriptional repression of MS4A1/CD20; chromatin immunoprecipitation showed Smad proteins directly bind the MS4A1 promoter. CD20 knockdown increases apoptosis, while stable CD20 overexpression confers resistance to TGF-β-induced apoptosis, establishing CD20 as a TGF-β target that promotes B cell survival.\",\n      \"method\": \"Oligonucleotide microarray; chromatin immunoprecipitation (ChIP) for Smad binding to MS4A1 promoter; CD20 knockdown and stable overexpression; apoptosis assays in vitro and in vivo\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ChIP establishing direct Smad binding, combined with gain- and loss-of-function genetic experiments with functional apoptosis readout; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"22665052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Farnesyltransferase inhibitors (FTIs, specifically L-744,832) upregulate CD20 at both mRNA and protein levels in B cell tumor lines and primary cells; ChIP reveals increased binding of transcription factors PU.1 and Oct-2 to CD20 promoter sequences upon FTI treatment, identifying a prenylation-dependent transcriptional regulatory mechanism for CD20 expression.\",\n      \"method\": \"Farnesyltransferase inhibitor treatment; qRT-PCR; flow cytometry; chromatin immunoprecipitation (ChIP) for PU.1 and Oct-2 at CD20 promoter; complement-dependent cytotoxicity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for transcription factor binding with pharmacologic and genetic perturbation; single lab\",\n      \"pmids\": [\"22843692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HDAC6 regulates CD20 protein levels post-transcriptionally by controlling CD20 mRNA translation; HDAC6 inhibition increases CD20 mRNA in the polysomal fraction without altering MS4A1 transcription, indicating translational rather than transcriptional regulation.\",\n      \"method\": \"HDAC6 pharmacologic inhibition and genetic knockdown; flow cytometry for CD20 protein; RT-PCR for MS4A1 mRNA; polysome fractionation; in vivo rituximab efficacy in mice\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — polysome fractionation directly measuring translational control, combined with pharmacologic and genetic HDAC6 perturbation and in vivo confirmation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"28830887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cryo-EM structure of full-length CD20 in complex with rituximab reveals CD20 as a compact double-barrel dimer; two rituximab Fabs each engage a composite epitope and an extensive homotypic Fab:Fab interface. The structure suggests rituximab cross-links CD20 into circular assemblies and provides a structural model for complement recruitment.\",\n      \"method\": \"Cryo-electron microscopy structure determination at 3.3 Å resolution; structure-function analysis of CD20-RTX complex\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure with functional interpretation; published in high-impact peer-reviewed journal, replicated in parallel by independent lab (PMID:32792392)\",\n      \"pmids\": [\"32079680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cryo-EM structures of full-length CD20 in complex with type I (rituximab, ofatumumab) and type II (obinutuzumab) therapeutic mAbs reveal mechanistic basis for type differences: type I mAb complexes act as molecular seeds for additional mAb recruitment and complement activation, while type II mAbs form terminal complexes that preclude additional mAb binding and complement component recruitment. Ofatumumab complexes display optimal geometry for complement recruitment among type I mAbs.\",\n      \"method\": \"Cryo-electron microscopy structures at 3.7–4.7 Å; binding thermodynamics measurements; structural comparison of type I vs type II mAb complexes\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple cryo-EM structures with thermodynamic validation; independent lab from PMID:32079680, replicating and extending structural findings\",\n      \"pmids\": [\"32792392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CRISPR/Cas9-mediated ablation of CD20 in resting B cells causes relocalization of IgM-class BCR and its interaction with coreceptor CD19, leading to transient B cell activation accompanied by internalization of B cell surface markers and a PAX5-to-BLIMP-1 transcriptional switch, metabolic reprogramming toward oxidative phosphorylation, and shift toward plasma cell development. Re-expression of CD20 restores the resting state, establishing CD20 as a gatekeeper of the resting B cell state that controls nanoscale receptor organization.\",\n      \"method\": \"CRISPR/Cas9 CD20 knockout in Ramos B cells; super-resolution microscopy for receptor nanoscale organization; rescue by CD20 re-expression; transcriptome analysis; metabolic profiling; rituximab treatment of naive human B cells in vitro and in vivo\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic ablation with rescue, multiple orthogonal readouts (receptor localization, transcriptomics, metabolomics, in vivo), replicated in primary human B cells and in vivo\",\n      \"pmids\": [\"33563755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MS4A1/CD20 mRNA is alternatively spliced into isoforms with distinct 5' UTRs (V1 and V3); V1 contains upstream open reading frames and a stem-loop that cooperatively inhibit polysome recruitment, making V1 translation-deficient while V3 supports CD20 protein expression. Splice-switching morpholino oligomers that redirect splicing from V1 to V3 enhance CD20 expression and rituximab-mediated cytotoxicity. In follicular lymphoma relapsing after mosunetuzumab, CD20 downregulation is accompanied by a V3-to-V1 splicing shift.\",\n      \"method\": \"RNA sequencing; polysome fractionation; morpholino splice-switching; CD20-knockout cell reconstitution with V1 or V3 mRNA; CAR T and bispecific antibody cytotoxicity assays; patient relapse RNA-seq\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution experiments with individual mRNA isoforms, polysome fractionation, splice-switching, and clinical validation; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"37683180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CD20 is abundantly expressed on B cell microvilli; binding of therapeutic mAbs (rituximab, ofatumumab, obinutuzumab) to CD20 on microvilli leads to antibody concentration-dependent B cell polarization and stabilization of microvilli protrusions. CD20 exists in distinct oligomeric states on the cell surface that differ in interaction with type I versus type II mAbs.\",\n      \"method\": \"Two-dye imager (TDI) DNA-PAINT super-resolution nanoscopy combined with lattice light-sheet microscopy; whole-cell volumetric imaging of endogenous CD20 on live immunological B cells\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — advanced live-cell nanoscopy revealing endogenous CD20 oligomeric states and membrane dynamics; single study, no genetic perturbation to confirm functional role of microvilli localization\",\n      \"pmids\": [\"39787234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"D393-CD20, an alternative splicing isoform of CD20 that lacks membrane expression, is translated in malignant B cells and generates CD4+ Th1 epitopes recognized by tumor-infiltrating T cells; D393-CD20-specific CD4 T cell clones kill autologous lymphoma B cells, and D393-CD20 peptide vaccination induces CD4 and CD8 T cell responses in HLA-humanized transgenic mice.\",\n      \"method\": \"RT-PCR detection of D393-CD20 translation; T cell clone functional assays (IFN-γ production, cytotoxicity); peptide vaccination of HLA-humanized transgenic mice; HLA class I and II presentation assays\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional T cell killing assays and in vivo vaccination; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"25449106\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD20 (MS4A1) is a B cell-specific four-transmembrane-domain phosphoprotein that forms a compact double-barrel dimer in the plasma membrane and functions as a gatekeeper of the B cell resting state by controlling nanoscale receptor organization: loss of CD20 causes IgM-BCR/CD19 co-receptor rearrangement, transient B cell activation, and transcriptional/metabolic reprogramming toward plasma cell fate; CD20 also regulates transmembrane Ca2+ conductance (particularly CD19-induced calcium responses), participates in early B cell G0-to-G1 cell cycle progression upon cross-linking, resides in cholesterol-dependent lipid raft microdomains where it associates with src-family kinases, is transcriptionally regulated by Smad proteins (downstream of TGF-β), by PU.1/Oct-2 (modulated by farnesyltransferase activity), and post-transcriptionally by HDAC6-dependent translational control and alternative splicing of its 5' UTR (with a translation-incompetent V1 isoform and a translation-competent V3 isoform); its extracellular loop disulfide (C167-C183) is required for binding of therapeutic antibodies such as rituximab, and structural studies reveal that type I antibodies (rituximab, ofatumumab) seed circular CD20 assemblies to recruit complement, while type II antibodies (obinutuzumab) form terminal complexes that preclude complement recruitment.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MS4A1 (CD20) is a B cell-restricted, four-transmembrane plasma membrane protein that functions as a gatekeeper of the resting B cell state by controlling the nanoscale organization of antigen receptors [#16]. Its expression is initiated during late pre-B cell development and increases with B cell maturation, yet its loss in mice produces no major defect in B cell development, antigen receptor signaling, or proliferation [#4, #9]. Mechanistically, CRISPR ablation of CD20 in resting B cells triggers relocalization of the IgM-BCR and its engagement with the CD19 coreceptor, driving transient activation, a PAX5-to-BLIMP-1 transcriptional switch, metabolic reprogramming toward oxidative phosphorylation, and a shift toward plasma cell fate that is reversed by CD20 re-expression [#16]; consistent with this coreceptor link, CD20-deficient B cells show reduced CD19-induced calcium responses [#9]. CD20 resides in cholesterol-dependent lipid raft microdomains enriched in src-family kinases, and antibody cross-linking clusters these rafts and drives a caspase-, mitochondria-, and Bcl-2-independent apoptotic pathway [#6, #7, #8]. Structurally, CD20 forms a compact double-barrel dimer whose extracellular C167–C183 disulfide is required for rituximab binding; type I antibodies (rituximab, ofatumumab) seed circular CD20 assemblies that recruit complement, while type II antibodies (obinutuzumab) form terminal complexes that preclude complement recruitment [#10, #14, #15]. CD20 abundance is controlled at multiple levels: transcriptionally by Smad proteins downstream of TGF-β (where CD20 promotes survival by resisting TGF-β-induced apoptosis) and by PU.1/Oct-2 under prenylation control, and post-transcriptionally by HDAC6-dependent translational control and by alternative 5' UTR splicing that generates a translation-deficient V1 and a translation-competent V3 isoform [#11, #12, #13, #17].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Established the earliest functional role of CD20 by showing that antibody cross-linking, but not monovalent engagement, drives resting B cells from G0 into G1 in concert with the Ig-signaling pathway, placing CD20 at an early activation checkpoint.\",\n      \"evidence\": \"B cell proliferation and cell-cycle assays with cross-linking versus Fab fragments, sequential antibody timing, and co-stimulant titration\",\n      \"pmids\": [\"3872456\", \"2415587\", \"3487090\", \"3492530\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No molecular signaling pathway downstream of CD20 defined\", \"Mechanism of how cross-linking couples to cell-cycle entry unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Tested whether CD20 is genetically required for B cell biology; knockout mice showed largely normal development and signaling, indicating CD20 is dispensable for core B cell functions in mice and reframing it as a modulator rather than an essential receptor.\",\n      \"evidence\": \"CD20 gene-disruption mice with development, signaling, proliferation, and calcium-uptake readouts\",\n      \"pmids\": [\"9634476\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Negative result does not exclude subtle or redundant roles\", \"Does not address human CD20 function or therapeutic relevance\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Refined CD20's role in calcium handling by showing that CD20-deficient B cells have reduced CD19-induced calcium responses, linking CD20 to coreceptor-dependent transmembrane Ca2+ movement.\",\n      \"evidence\": \"CD20-deficient mice with CD19- and IgM-induced intracellular calcium assays and developmental flow cytometry\",\n      \"pmids\": [\"14688067\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD20 itself conducts ions or acts indirectly via CD19 unresolved\", \"Molecular link between CD20 and the calcium machinery undefined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Connected CD20 to membrane microdomain biology by showing its raft association is cholesterol-dependent and that cross-linking clusters rafts to engage src-family kinases and drive a non-canonical apoptotic pathway.\",\n      \"evidence\": \"Lipid raft fractionation, cholesterol depletion/enrichment, extracellular-domain mutagenesis, kinase inhibition, and apoptosis assays\",\n      \"pmids\": [\"12200688\", \"12383196\", \"12835728\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the src-family kinases and apoptotic effectors not defined\", \"Physiological relevance of cross-linking-induced apoptosis unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined the molecular determinant of therapeutic antibody binding by showing the extracellular C167–C183 disulfide is required for rituximab recognition and that surface CD20 binds with higher avidity than purified protein.\",\n      \"evidence\": \"E. coli expression and purification, circular dichroism, cysteine mutagenesis, reduction/reoxidation, and rituximab affinity measurements\",\n      \"pmids\": [\"16285718\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full conformational epitope not resolved at this stage\", \"Oligomeric state on the membrane not directly visualized\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Resolved how CD20 expression is transcriptionally controlled, identifying Smad-mediated repression downstream of TGF-β (with CD20 promoting survival) and PU.1/Oct-2 activation under prenylation control.\",\n      \"evidence\": \"ChIP for Smad, PU.1 and Oct-2 at the MS4A1 promoter, knockdown/overexpression, farnesyltransferase inhibition, and apoptosis/CDC assays\",\n      \"pmids\": [\"22665052\", \"22843692\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TGF-β/Smad and PU.1/Oct-2 inputs are integrated unknown\", \"Mechanism by which CD20 confers apoptosis resistance not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extended CD20 regulation beyond transcription by showing HDAC6 controls CD20 protein levels through translational regulation of its mRNA, with direct relevance to rituximab efficacy.\",\n      \"evidence\": \"HDAC6 pharmacologic inhibition and knockdown, polysome fractionation, mRNA quantification, and in vivo rituximab efficacy\",\n      \"pmids\": [\"28830887\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular link between HDAC6 and the CD20 translation machinery not defined\", \"Acetylation substrate mediating the effect unidentified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Provided the structural basis for CD20 architecture and antibody-class differences, revealing a double-barrel dimer and explaining why type I antibodies seed complement-recruiting assemblies while type II antibodies form terminal complexes.\",\n      \"evidence\": \"Cryo-EM structures of full-length CD20 bound to type I and type II mAbs with binding thermodynamics, from two independent labs\",\n      \"pmids\": [\"32079680\", \"32792392\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of unliganded native oligomers not resolved\", \"Endogenous oligomeric distribution on live cells not addressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established CD20's core physiological function as a gatekeeper of the resting B cell state, showing its loss reorganizes the IgM-BCR/CD19 axis and drives a transcriptional and metabolic shift toward plasma cell fate that is reversible upon re-expression.\",\n      \"evidence\": \"CRISPR knockout with rescue, super-resolution microscopy, transcriptomics, metabolic profiling, and primary human B cell/in vivo validation\",\n      \"pmids\": [\"33563755\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular interaction between CD20 and BCR/CD19 not structurally defined\", \"How CD20 physically constrains receptor nanoscale organization unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified a post-transcriptional resistance mechanism, showing 5' UTR alternative splicing generates a translation-deficient V1 and translation-competent V3 isoform, with V3-to-V1 shifts driving CD20 loss in lymphoma relapse.\",\n      \"evidence\": \"RNA-seq, polysome fractionation, splice-switching morpholinos, isoform reconstitution, immunotherapy cytotoxicity assays, and patient relapse RNA-seq\",\n      \"pmids\": [\"37683180\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream regulators controlling the V1/V3 splicing decision unknown\", \"Generalizability across lymphoma subtypes not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Localized endogenous CD20 to B cell microvilli and showed antibody binding induces polarization and microvilli stabilization, with distinct oligomeric states differentially engaging type I versus type II mAbs.\",\n      \"evidence\": \"DNA-PAINT super-resolution nanoscopy with lattice light-sheet imaging of endogenous CD20 on live B cells\",\n      \"pmids\": [\"39787234\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic perturbation to confirm functional role of microvilli localization\", \"Molecular basis distinguishing the oligomeric states undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CD20 mechanically organizes the BCR/CD19 nanocluster and whether its oligomeric and microvilli distribution directly governs ion conductance and resting-state maintenance remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of CD20 in complex with BCR or CD19\", \"Mechanism coupling CD20 oligomeric state to calcium conductance undefined\", \"Direct effectors of CD20-dependent receptor confinement unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7, 8, 16, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 9, 16]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [6, 11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CD19\", \"MS4A1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}